anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a use of a composition for preparing a drug for squamous cell carcinoma of the skin, wherein the composition comprises Naphtho[1,2-b]furan-4,5-dione (NFD). The purpose of the present invention is to discover the medical use of NFD in other cancers. At the same time, in order to overcome the shortcoming of low water solubility, the present invention uses the electrospinning technology to synthesize NFD for forming nanofibers so as to improve its water solubility and physicochemical properties and show the anticancer effect on squamous cell carcinoma of the skin. The concentration of Naphtho[1,2-b]furan-4,5-dione (NFD) must be greater than 0.5μg/ml. Naphtho[1,2-b]furan-4,5-dione (NFD) must be dissolved in dimethyl sulfoxide (DMSO) or ethanol. The nanofibers are manufactured by the steps of mixing the above-described composition with a solvent to form a first solution; stirring and mixing the first solution with hydroxypropyl s-cyclodextrin (HPBCD) to form a second solution; adding polyvinyl pyrrolidone (PVP) in the second solution and mixing to form a third solution; and using the electrospinning technology to place the third solution in the syringe and ejecting and collecting the nanofibers by high voltage, which can spray the solution to become fibers with extremely fine radius such that there is a better absorption efficiency for cells and human body. The concentration of the composition must be greater than 0.125μg/ml. The nanofibers are added in a topical liniment or a topical pharmaceutical product. The present invention also provides a use of nanofibers for preparing a drug for squamous cell carcinoma of the skin.
Upper gastrointestinal bleeding (UGIB) is bleeding in the upper part of the gastrointestinal tract with an acidic and dynamic environment that limits the application of conventional hemostatic materials. This study focuses on the development of N-[(2-hydroxy-3-trimethylammonium) propyl] chitosan chloride/phytic acid (HTCC/PA, HP) powders with fast hemostatic capability and strong acid resistance, for potential applications in managing UGIB. Upon contact with liquids within 5 seconds, HP powders rapidly transform into hydrogels, forming ionic networks through electrostatic interactions. The ionic crosslinking process facilitates the HP powders with high blood absorption (3.4 times of self-weight), sufficient tissue adhesion (5.2 and 6.1 kPa on porcine skin and stomach, respectively), and hemostasis (within 15 seconds for in vitro clotting). Interestingly, the PA imparts the HP powders with strong acid resistance (69.8% mass remaining after 10 days of incubation at pH 1) and on-demand removable sealing while HTCC contributes to fast hemostasis and good wet adhesion. Moreover, the HP powders show good biocompatibility and promote wound healing. Therefore, these characteristics highlight the promising clinical potential of HP powders for effectively managing UGIB.
The prevalence of alopecia has increased recently. Hair loss is often accompanied by the resting phase of hair follicles (HFs). Dermal papilla (DP) plays a crucial role in HF development, growth, and regeneration. Activating DP can revive resting HFs. Augmenting WNT/β-catenin signaling stimulates HF growth. However, the factors responsible for activating resting HFs effectively are unclear. In this study, we investigated epidermal cytokines that can activate resting HFs effectively. We overexpressed β-catenin in both in vivo and in vitro models to observe its effects on resting HFs. Then, we screened potential epidermal cytokines from GEO DATASETs and assessed their functions using mice models and skin-derived precursors (SKPs). Finally, we explored the molecular mechanism underlying the action of the identified cytokine. The results showed that activation of WNT/β-catenin in the epidermis prompted telogen-anagen transition. Keratinocytes infected with Ctnnb1-overexpressing lentivirus enhanced SKP expansion. Subsequently, we identified endothelin 1 (ET-1) expressed higher in hair-growing epidermis and induced the proliferation of DP cells and activates telogen-phase HFs in vivo. Moreover, ET-1 promotes the proliferation and stemness of SKPs. Western blot analysis and in vivo experiments revealed that ET-1 induces the transition from telogen-to-anagen phase by upregulating the PI3K/AKT pathway. These findings highlight the potential of ET-1 as a promising cytokine for HF activation and the treatment of hair loss.
Examples of the present disclosure describe systems and methods for predicting the reading time and/or reading complexity of a breast image. In aspects, a first set of data relating to the reading time of breast images may be collected from one or more data sources, such as image acquisition workstations, image review workstations, and healthcare professional profile data. The first set of data may be used to train a predictive model to predict/estimate an expected reading time and/or an expected reading complexity for various breast images. Subsequently, a second set of data comprising at least one breast image may be provided as input to the trained predictive model. The trained predictive model may output an estimated reading time and/or reading complexity for the breast image. The output of the trained predictive model may be used to prioritize mammographic studies or optimize the utilization of available time for radiologists.
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening autoimmune disorder caused by a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency. Caplacizumab, an anti-von Willebrand factor nanobody, is approved for iTTP treatment, reducing the need for therapeutic plasma exchange (TPE) and improving platelet count recovery and survival. We conducted a retrospective study on 42 acute iTTP cases in Austria and Germany, treated with a modified regimen aimed at avoiding TPE if platelet count increased after the first caplacizumab dose. Baseline characteristics and patient outcomes were compared with a control group of 59 patients with iTTP receiving frontline treatment with TPE, caplacizumab, and immunosuppression. The main outcome was the time to platelet count normalization. Secondary outcomes included clinical response, exacerbation, refractory iTTP, iTTP-related deaths, and the time to platelet count doubling. The median time to platelet count normalization was similar between the 2 cohorts (3 and 4 days; P = .31). There were no significant differences in clinical response, exacerbations, refractoriness, iTTP-related deaths, or time to platelet count doubling, reflecting the short-term treatment response. Four patients did not respond to the first caplacizumab dose, and TPE was subsequently initiated. Cytomegalovirus infection, HIV/hepatitis B virus coinfection, an ovarian teratoma with associated antiplatelet antibodies, and multiple platelet transfusions before the correct diagnosis may have impeded the immediate treatment response in these patients. In conclusion, caplacizumab and immunosuppression alone, without TPE, rapidly controlled thrombotic microangiopathy and achieved a sustained clinical response in iTTP. Our study provides a basis for TPE-free iTTP management in experienced centers via shared decision-making between patients and treating physicians.
One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand. In certain embodiments, a ligand is bound to only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, both of the oligonucleotide strands of the double-stranded oligonucleotide independently comprise a bound ligand. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. In certain embodiments, a phosphate linkage in one or both of the strands of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5.beta.-cholanic acid.  Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety. In certain embodiments, a phosphate linkage of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5.beta.-cholanic acid. The ligand improves the pharmacokinetic properties of the oligonucleotide.
Oxycodone Hydrochloride Capsules are an agonist, available as a hard gelatin capsule 5 mg for oral administration. The chemical name is (5R,9R,13S,14S)-4,5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride. The molecular weight is 351.82. 

Its molecular formula is C18H21NO4∙HCl, and it has the following chemical structure.

Oxycodone hydrochloride is a white, odorless crystalline powder derived from the opium alkaloid, thebaine. It is soluble in water and slightly soluble in alcohol. 

The inactive ingredients in Oxycodone Hydrochloride Capsules 5 mg include: colloidal silicon dioxide, gelatin, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium starch glycolate, FD&C yellow #6, titanium dioxide, yellow iron oxide, shellac glaze, iron oxide black, propylene glycol, and ammonium hydroxide.
The investigators will recruit and enroll 76 patients (between 18 and 30 years of age) who have had persistent symptoms consistent with PCS for at least 4 weeks, but not more than 6 months, after the initial injury. The experimental group will contain 38 subjects. Each study subject will receive two hats, which contain the integrated PEMF device, this will be done to ensure continuity of treatment in case that one of the hats stops working due to the battery running out. The subjects will receive PEMF treatment for 15 minutes three times per day for 6 weeks. Upon enrollment and at the end of the 6-week treatment period, all subjects will undergo a comprehensive assessment that will include symptom inventories, neuropsychological tests, qEEG measurement and near-infrared spectroscopy. The investigators will conduct a 3-month follow-up to assess longer-term outcomes.
BACKGROUND: Major guidelines consistently recommend 5 years of postoperative surveillance for patients with colorectal cancer. However, they differ in their recommendations for examination intervals and whether they should vary according to disease stage. Furthermore, there are no reports on the cost-effectiveness of the different surveillance schedules. The objective of this study is to identify the most cost-effective surveillance intervals after curative resection of colorectal cancer.
METHODS: A total of 3701 patients who underwent curative surgery for colorectal cancer at the National Cancer Center Hospital were included. A cost-effectiveness analysis was conducted for the five surveillance strategies with reference to the guidelines. Expected medical costs and quality-adjusted life years after colorectal cancer resection were calculated using a state-transition model by Monte Carlo simulation. The incremental cost-effectiveness ratio per quality-adjusted life years gained was calculated for each strategy, with a maximum acceptable value of 43 500-52 200 USD (5-6 million JPY).
RESULTS: Stages I, II and III included 1316, 1082 and 1303 patients, respectively, with 45, 140 and 338 relapsed cases. For patients with stage I disease, strategy 4 (incremental cost-effectiveness ratio $26 555/quality-adjusted life year) was considered to be the most cost-effective, while strategies 3 ($83 071/quality-adjusted life year) and 2 ($289 642/quality-adjusted life year) exceeded the threshold value. In stages II and III, the incremental cost-effectiveness ratio for strategy 3 was the most cost-effective option, with an incremental cost-effectiveness ratio of $18 358-22 230/quality-adjusted life year.
CONCLUSIONS: In stage I, the cost-effectiveness of intensive surveillance is very poor and strategy 4 is the most cost-effective. Strategy 3 is the most cost-effective in stages II and III.
BACKGROUND: Phalloplasty is among the most complex and technically demanding reconstructive procedures. As a larger pool of surgeons perform this difficult procedure, more patients will present with major complications. There are few published data on the comprehensive evaluation and management of these patients, particularly those needing correction of multiple ongoing complications, which may require consideration of starting over with a new microsurgical procedure versus salvage of the existing flap.
METHODS: A literature review on complications of phalloplasty was conducted in combination with drawing upon the experience of 2 high-volume phalloplasty teams (Johns Hopkins/Harvard and GU Recon Clinic/Buncke Clinic) in treating patients with severe postsurgical issues. The purpose was to analyze critical factors and develop algorithms for secondary revision.
RESULTS: Common complications of phalloplasty include urethral strictures and fistulas, diverticula, excess bulk, phalloplasty malposition, hypertrophic or keloidal scarring, and partial or total flap loss. In severe cases, local flaps or free flaps may be required for reconstruction. The decision to revise the existing neophallus or start over with a new flap for phalloplasty is particularly critical. Multidisciplinary team collaboration is essential to develop comprehensive plans that will resolve multiple concomitant problems while meeting patient goals for a functional and aesthetic neophallus.
CONCLUSIONS: Preserving the original flap for phalloplasty is ideal when feasible. Additional local or free flaps are sometimes necessary in situations of significant tissue loss. In severe cases, complete redo phalloplasty is required. The algorithms proposed provide a conceptual framework to guide surgeons in analyzing and managing severe complications after phalloplasty.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, V.
BACKGROUND: Neurosurgeons treat nonfunctioning pituitary adenomas by surgical resection. Based on the adherence of the tumor to the normal pituitary gland, operative risks may include hormone replacement therapy for postoperative hypopituitarism with gross total resection that injures the gland or recurrent tumor with subtotal resection and purposeful avoidance of gland manipulation. None of the patients presented in this article had a preoperative preference regarding extent of resection. This study aimed to evaluate postoperative patient preferences regarding extent of resection.
METHODS: Adult patients who underwent resection of adenomas between 2015 and 2023 were retrospectively reviewed and surveyed. After surgery, participating patients were asked for their preference regarding 100% tumor resection with lifelong daily hormone replacement therapy versus 90% tumor resection with a chance of recurrence in the hypothetical situation where the neurosurgeon encounters tumor adherent to the normal gland.
RESULTS: Of the 73 patients included, 54 (74.0%) responded to the survey, with the majority (36 [66.7%]) preferring 90% resection with the chance of tumor recurrence. Tumor recurrence (odds ratio 2.3, 95% confidence interval 2.1-2.5, P = 0.03) and steroid avoidance (odds ratio 2.2, 95% confidence interval 2.0-2.4, P = 0.04) were the 2 variables that were significant predictors of patient preference in multivariate regression analysis.
CONCLUSIONS: Although patients may not have the preoperative insight or experience to have a strong conviction regarding the extent of adenoma resection, the consequences following surgery clearly influence their preference. Most patients in our study, including patients with gross total resection and especially patients who experienced side effects of steroid therapy, preferred subtotal resection with the chance of tumor recurrence over hormone replacement therapy.
PCT No. PCT/GB89/00698 Sec. 371 Date Nov. 28, 1990 Sec. 102(e) Date Nov. 28, 1990 PCT Filed Jun. 22, 1989 PCT Pub. No. WO89/12684 PCT Pub. Date Dec. 28, 1989.The invention relates to DNA from fowlpox virus (FPV) providing a non-essential region for the insertion of foreign genes thereinto and thence the construction of a vector for homologous recombination with a wild type FPV, whereby the resulting recombinant FPV can be used for vaccination of animals, especially chickens. In this invention, the non-essential region consists substantially of a length of DNA from the long unique sequence of the terminal inverted repeat (TIR) of FPV or from the region at FPV which corresponds approximately to the HindIII D fragment genes D8 and D9 in vaccinia virus.
NEW MATERIAL:A compound shown by formulaI[R is H, lower alkyl, etc.; R2 is H, or a group shown by the formula II (X is H, amino-protecting group; Y is H, OH, etc.); Z is H, or Y1 (Y is hydroxyl-protecting group); aromatic amino acid is L-form; 1-amino-2-(4-hydroxyphenyl)ethylphosphonic acid part shows negative rotatory power]. EXAMPLE:N-( N-t-Butoxycarbonyl-o-benzyl-L-tyrosyl )-(-)-1-amino-2-(4-benzyloxyphenyl)ethylphosphonic acid diethyl ester. USE:An intermediate for phosphorus-containing oligopeptide. PROCESS:A compound shown by the formula IV obtained from a compound shown by the formula III, an alkyl halide, etc. is dissolved in thionyl chloride, and boiled to give a compound shown by the formula V. This compound is reacted with a trialkyl phosphite, etc. to give a compound shown by the formula VI, which is reacted with hydroxylamine, etc., and reduced to give a compound shown by the formula VII. This compound is reacted with a tyrosine derivative, etc. in the presence of a condensation agent to give a compound shown by the formula VIII, which is hydrolyzed in an aqueous solution of hydrochloric acid, etc. to give a compound shown by the formula IX.
Cohort 1b patients are randomized onto treatment. After 6 months, all patients are on drug.
The invention relates to a medicine for curing varicosity, which belongs to the traditional Chinese medicine field. The medicine is made from raw materials of alkanna tinctoria, Chinese angelica root, milk vetch, achyranthes cyathula root, red peony root, rhizome of Sichuan lovage, pseudostellaria root, love peach seed, safflower and honey-fried licorice root in proportion by weight. Putting the raw material medicines into a marmite and adding appropriate water for soaking: first, using furious fire to boil, then using small fire to heat for half an hour then filtering the liquid medicine once a day. By using the medicine, the blood vessel can be warmed through quickly, the blood is nourished and the blood circulation is promoted. The symptom such as numbness and hurt of body as well as hurt of the lower limbs after walking and etc. is eliminated. By taking the medicine for three months, the veins are gradually through without being impeded, the blood circulation speeds up, the varicosity is improved obviously, the blood viscosity and the platelet aggregation are declined obviously, the ulcer surface is sealed, the veins which are occlusive and necrotic are smoothed and eased, and new granulation starts to grow on the necrotic skin. By the invention, 120 cases of patients suffering from varicosity are cured, the cure rate is 65.83 percent, and the effective rate is 92 percent.
<P>PROBLEM TO BE SOLVED: To provide a measurement data processing system easily generating measurement data from ultrasonic data obtained by ultrasonic imaging and collecting and statistically processing the generated measurement data.  <P>SOLUTION: This measurement data processing system is provided with ultrasonic diagnostic equipment 101, and a measurement data processor 80 processing the measurement data transmitted from the ultrasonic diagnostic equipment 101 via a network 100. The ultrasonic diagnostic equipment 101 measures the ultrasonic data generated by the ultrasonic imaging based on examination information input from an operation section 8, adds measurement classification information corresponding to the measurement data produced by the measurement and the examination information thereto, and transmits them to the measurement data processor 80. Meanwhile, the measurement data processor 80 intensively stores the measurement data received from the ultrasonic diagnostic equipment 101. The measurement data processor searches measurement data added with the measurement classification information and search information obtained from a terminal device 201a, in the stored data, statistically processing the searched measurement data and generates the statistic data.  <P>COPYRIGHT: (C)2008,JPO&INPIT
1466957 Enzyme mixtures BOEHRINGER INGELHEIM GmbH 19 April 1974 [21 April 1973] 17320/74 Heading C3H [Also in Division C6] An enzyme mixture useful in the mashing of cereal grains consists essentially of amyloglucosidase and at least one microbial and/or vegetable protease, and can (optionally) include cellulase, hemi-cellulase, pectinase, pentosanase and #-glucanase. It is, however, to be free of α-amylase. A preferred mixture contains 500-1500 units per gram of amyloglucosidase and 50-250 units per gram of proteases standardized as to activity by a starch or lactose carrier material. Of the protease activity 70% may be derived from vegetable and 30% from bacterial sources, e.g. papain and B. subtilis, respectively. Fungal and bacterial proteases may also be combined. Preferably the pH and temperature optima of the enzymes in the mixture do not differ by more than 0À6 pH and 8‹ C. (pH 5À0, temperature 58‹ C.).